6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      AKT-driven epithelial-mesenchymal transition is affected by copper bioavailability in HER2 negative breast cancer cells via a LOXL2-independent mechanism

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The main mechanism underlying cancer dissemination is the epithelial to mesenchymal transition (EMT). This process is orchestrated by cytokines like TGFβ, involving “non-canonical” AKT- or STAT3-driven pathways. Recently, the alteration of copper homeostasis seems involved in the onset and progression of cancer.

          Methods

          We expose different breast cancer cell lines, including two triple negative (TNBC) ones, an HER2 enriched and one cell line representative of the Luminal A molecular subtype, to short- or long-term copper-chelation by triethylenetetramine (TRIEN). We analyse changes in the expression of EMT markers (E-cadherin, fibronectin, vimentin and αSMA), in the levels and activity of extracellular matrix components (LOXL2, fibronectin and MMP2/9) and of copper homeostasis markers by Western blot analyses, immunofluorescence, enzyme activity assays and RT-qPCR. Boyden Chamber and wound healing assays revealed the impact of copper chelation on cell migration. Additionally, we explored whether perturbation of copper homeostasis affects EMT prompted by TGFβ. Metabolomic and lipidomic analyses were applied to search the effects of copper chelation on the metabolism of breast cancer cells. Finally, bioinformatics analysis of data on breast cancer patients obtained from different databases was employed to correlate changes in kinases and copper markers with patients’ survival.

          Results

          Remarkably, only HER2 negative breast cancer cells differently responded to short- or long-term exposure to TRIEN, initially becoming more aggressive but, upon prolonged exposure, retrieving epithelial features, reducing their invasiveness. This phenomenon may be related to the different impact of the short and prolonged activation of the AKT kinase and to the repression of STAT3 signalling. Bioinformatics analyses confirmed the positive correlation of breast cancer patients’ survival with AKT activation and up-regulation of CCS. Eventually, metabolomics studies demonstrate a prevalence of glycolysis over mitochondrial energetic metabolism and of lipidome changes in TNBC cells upon TRIEN treatment.

          Conclusions

          We provide evidence of a pivotal role of copper in AKT-driven EMT activation, acting independently of HER2 in TNBC cells and via a profound change in their metabolism. Our results support the use of copper-chelators as an adjuvant therapeutic strategy for TNBC.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s13402-022-00738-w.

          Related collections

          Most cited references34

          • Record: found
          • Abstract: found
          • Article: not found

          New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer

          Epithelial-mesenchymal transition (EMT) is a cellular programme that is known to be crucial for embryogenesis, wound healing and malignant progression. During EMT, cell-cell and cell-extracellular matrix interactions are remodelled, which leads to the detachment of epithelial cells from each other and the underlying basement membrane, and a new transcriptional programme is activated to promote the mesenchymal fate. In the context of neoplasias, EMT confers on cancer cells increased tumour-initiating and metastatic potential and a greater resistance to elimination by several therapeutic regimens. In this Review, we discuss recent findings on the mechanisms and roles of EMT in normal and neoplastic tissues, and the cell-intrinsic signals that sustain expression of this programme. We also highlight how EMT gives rise to a variety of intermediate cell states between the epithelial and the mesenchymal state, which could function as cancer stem cells. In addition, we describe the contributions of the tumour microenvironment in inducing EMT and the effects of EMT on the immunobiology of carcinomas.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            TGF-beta-induced epithelial to mesenchymal transition.

            During development and in the context of different morphogenetic events, epithelial cells undergo a process called epithelial to mesenchymal transition or transdifferentiation (EMT). In this process, the cells lose their epithelial characteristics, including their polarity and specialized cell-cell contacts, and acquire a migratory behavior, allowing them to move away from their epithelial cell community and to integrate into surrounding tissue, even at remote locations. EMT illustrates the differentiation plasticity during development and is complemented by another process, called mesenchymal to epithelial transition (MET). While being an integral process during development, EMT is also recapitulated under pathological conditions, prominently in fibrosis and in invasion and metastasis of carcinomas. Accordingly, EMT is considered as an important step in tumor progression. TGF-beta signaling has been shown to play an important role in EMT. In fact, adding TGF-beta to epithelial cells in culture is a convenient way to induce EMT in various epithelial cells. Although much less characterized, epithelial plasticity can also be regulated by TGF-beta-related bone morphogenetic proteins (BMPs), and BMPs have been shown to induce EMT or MET depending on the developmental context. In this review, we will discuss the induction of EMT in response to TGF-beta, and focus on the underlying signaling and transcription mechanisms.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

              Glycogen synthase kinase-3 (GSK3) may be the busiest kinase in most cells, with over 100 known substrates to deal with. How does GSK3 maintain control to selectively phosphorylate each substrate, and why was it evolutionarily favorable for GSK3 to assume such a large responsibility? GSK3 must be particularly adaptable for incorporating new substrates into its repertoire, and we discuss the distinct properties of GSK3 that may contribute to its capacity to fulfill its roles in multiple signaling pathways. The mechanisms regulating GSK3 (predominantly post-translational modifications, substrate priming, cellular trafficking, protein complexes) have been reviewed previously, so here we focus on newly identified complexities in these mechanisms, how each of these regulatory mechanism contributes to the ability of GSK3 to select which substrates to phosphorylate, and how these mechanisms may have contributed to its adaptability as new substrates evolved. The current understanding of the mechanisms regulating GSK3 is reviewed, as are emerging topics in the actions of GSK3, particularly its interactions with receptors and receptor-coupled signal transduction events, and differential actions and regulation of the two GSK3 isoforms, GSK3α and GSK3β. Another remarkable characteristic of GSK3 is its involvement in many prevalent disorders, including psychiatric and neurological diseases, inflammatory diseases, cancer, and others. We address the feasibility of targeting GSK3 therapeutically, and provide an update of its involvement in the etiology and treatment of several disorders.
                Bookmark

                Author and article information

                Contributors
                anastasia.deluca@uniroma2.it
                luisa.rossi@uniroma2.it
                Journal
                Cell Oncol (Dordr)
                Cell Oncol (Dordr)
                Cellular Oncology (Dordrecht)
                Springer Netherlands (Dordrecht )
                2211-3428
                2211-3436
                1 December 2022
                1 December 2022
                2023
                : 46
                : 1
                : 93-115
                Affiliations
                [1 ]GRID grid.6530.0, ISNI 0000 0001 2300 0941, Department of Biology, , University of Rome “Tor Vergata”, ; Via Della Ricerca Scientifica 1, 00133 Rome, Italy
                [2 ]GRID grid.416651.1, ISNI 0000 0000 9120 6856, Core Facilities High Resolution NMR Unit, , Istituto Superiore Di Sanità, ; 00161 Rome, Italy
                [3 ]GRID grid.7010.6, ISNI 0000 0001 1017 3210, Department of Life and Environmental Sciences, , Polytechnic University of Marche, ; Via Brecce Bianche, 60131 Ancona, Italy
                [4 ]GRID grid.6530.0, ISNI 0000 0001 2300 0941, PhD program in Cellular and Molecular Biology, Department of Biology, , University of Rome “Tor Vergata”, Via della Ricerca Scientifica 1, ; 00133 Rome, Italy
                Article
                738
                10.1007/s13402-022-00738-w
                9947069
                36454513
                5268c1bd-3563-4c69-a652-106098e2ec90
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 23 October 2022
                Funding
                Funded by: Crowd.Science platform (https://crowd.science)
                Award ID: “Measuring Copper and Iron for human and planet health”
                Award ID: “Measuring Copper and Iron for human and planet health”
                Award ID: “Measuring Copper and Iron for human and planet health”
                Award ID: “Measuring Copper and Iron for human and planet health”
                Award Recipient :
                Funded by: by POR FESR Lazio 2014-2020-Progetti strategici 2019
                Award ID: AQUAFOOD
                Award ID: AQUAFOOD
                Award Recipient :
                Funded by: Università degli Studi di Roma Tor Vergata
                Categories
                Original Article
                Custom metadata
                © Springer Nature Switzerland AG 2023

                Oncology & Radiotherapy
                breast cancer,epithelial to mesenchymal transition,copper,trien,akt,tgfβ,loxl2,her2
                Oncology & Radiotherapy
                breast cancer, epithelial to mesenchymal transition, copper, trien, akt, tgfβ, loxl2, her2

                Comments

                Comment on this article